ELAN Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $1.137 billion, a 10% increase year-over-year; 9% organic constant currency growth.

Adjusted EBITDA: $198 million, up $35 million from the previous year.

Adjusted EPS: $0.19, an increase of $0.06 year-over-year.

Gross Margin: Increased by 90 basis points to 53.1%.

Cash Flow: Cash generated from operations was $219 million, compared to $162 million in Q3 2024.

Net Debt: Approximately $3.3 billion with a net leverage ratio of 3.7x, better than expectations.

2Strategic Updates and Business Highlights

Growth Drivers: U.S. Farm Animal segment grew 20%, and U.S. Pet Health grew 9%, driven by innovative products like Credelio Quattro and Zenrelia.

Innovation Performance: Year-to-date innovation revenue reached $655 million, with a raised full-year target of $840 million to $880 million.

Product Launches: Credelio Quattro achieved blockbuster status in under 8 months, while Zenrelia showed strong momentum with significant market share gains in the U.S. and international markets.

Debt Refinancing: Successfully refinanced a $2.1 billion Term Loan B facility, extending maturities and reducing costs.

Operational Efficiency: The Elanco Ascend initiative aims to enhance productivity and reduce costs.

3Forward Guidance and Outlook

2025 Guidance:

Organic constant currency growth expected between 6% and 6.5%.

Adjusted EBITDA guidance raised to $880 million to $900 million.

Adjusted EPS guidance increased to $0.91 to $0.94.

2026 Outlook: Anticipates continued growth driven by innovation, with expectations for improved pricing strategies and operational efficiencies.

4Bad News, Challenges, or Points of Concern

Tariff Impact: Expected net impact of $10 million to $14 million on adjusted EBITDA due to tariffs, though manageable.

Competitive Pressures: Increased competition in the pet health market, particularly for new product launches, could impact market share.

Consumer Macro Pressures: Potential declines in U.S. vet visits and consumer reticence around therapies could affect future growth.

OpEx Growth: Operating expenses are projected to grow by 10% in Q4 2025, raising concerns about sustaining profitability amidst increased investments.

5Notable Q&A Insights

Credelio Quattro: Clarified that it reached $100 million in sales year-to-date, not just in Q3. The product has significant growth potential, with a strong market presence and high reorder rates.

Zenrelia Label Updates: The removal of certain warnings from the label is expected to enhance market acceptance and sales growth.

Investment Strategy: The company will continue to invest in innovation and marketing, leveraging data-driven approaches to maximize returns.

Market Dynamics: Elanco's diversified portfolio and strong market fundamentals position it well against competitive pressures, with a focus on maintaining growth in both pet and farm animal segments. Overall, Elanco demonstrated strong performance in Q3 2025, with significant growth in key segments and a positive outlook for the future, despite facing competitive and macroeconomic challenges.